|
Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on investments in biopharmaceuticals and laboratory infrastructure companies. Ron joined the Sprout healthcare team in January 1998, and was part of the team that spun out of the Sprout Group (the venture capital affiliate of Credit-Suisse) in 2005 to form NLV. Prior to joining Sprout, Ron was a consultant with Coopers & Lybrand Consulting and then with The Health Care Group (a division of the Interpublic Group of companies) for a combined 4 years. His consulting work focused on strategic and operational engagements for clients in the pharmaceutical and medical device industries. Prior to entering the consulting field, Ron held a number of sales and marketing positions for a combined 8 years with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (MBA) and Cornell University (BS). Ron was the lead investor and served on the boards of Cerexa, Inc. and Aspreva Pharmaceuticals up until their recent acquisitions by Forest Laboratories and Gallenica Group, respectively. Ron has served on a number of other boards for companies in a broad range of healthcare sectors including biotech, laboratory services, health care information technology, and laboratory instrumentation.
Board Seats:
Spine Wave,
Stromedix
Contact Information:
ron@nlvpartners.com
(646) 871-6400
|
 |
